Stroke, Cerebral Hemorrhage, Hemiplegia, and Migraine Panel
Use
This test is intended for individuals with clinical or suspected diagnosis of stroke, cerebral hemorrhage, hemiplegia, or migraine, as well as those with a family history of these conditions. It aims to aid in the diagnosis by identifying genetic variants associated with these disorders.
Special Instructions
This test can be ordered through the exome and genome platforms with additional options for exome-wide CNV Analysis and STAT testing. Standard institutional pricing is available through signing into the platform.
Limitations
The performance of this panel is validated under CAP and CLIA regulations. However, it has not been cleared or approved by the FDA, which may affect its availability or acceptance in certain jurisdictions. The presence of a familial or personal history of the diseases under study enhances the test’s utility for diagnostic purposes.
New York Approved
Methodology
NGS (CGP)
Biomarkers
Result Turnaround Time
14-21 days
Related Documents
For more information, please review the documents below
Specimen
Whole Blood
Volume
Not provided
Minimum Volume
Not provided